PRODUCTS

AR Chip for T-TAS01 (RUO)


AR Chip for T-TAS®01
FOR RESEARCH USE ONLY

BACKGROUND

Vascular haemostasis is achieved by complex physical and biochemical reactions of platelets and coagulation factors at the site of injury. Under blood flow conditions, platelet activation and coagulation processes are dynamically affected by platelets, coagulation factors, and their inhibitors. 

WHAT is the AR Chip?

AR chip has a 80 μm thick flow chamber coated with collagen and tissue thromboplastin, and mimics in vivo blood flow with 600/s shear stress, which represents shear stresses in large arteries. 

HOW does it work?

Whole blood is perfused at a constant flow rate at 37°C through the flow chamber pre-coated with tissue thromboplastin and collagen. The flow pressure changes are monitored by the pressure transducer located upstream in the chamber. Thrombus formation within the flow chamber increases flow resistance causing the pressure to increase. OST (time to 10 kPa: T10) is the lag time for the flow pressure to reach 10 kPa due to partial occlusion of the capillary. OT (occlusion time) is the lag time for the flow pressure to increase by 60 kPa from baseline owing to near complete occlusion of the capillary by . The area under the curve (AUC) is the area under the flow pressure vs. time curve and is related to overall thrombus formation.

 

A distinct advantage of using a flow chamber system for the measurement of thrombus formation is the correlation with the in vivo thrombus formation process. Scanning electron microscopic (SEM) analyses of thrombi inside AR chip showed that thrombi formed within the microchip capillaries under flow condition were tightly packed and contained numerous activated platelets. In contrast, thrombi formed under static condition was mainly composed of erythrocytes surrounded by fibrin fibers.

 

SEM analysis of thrombi with / without shear stress

AR CHIP ASSAY SYSTEM

AR Chip for T-TAS®01 Reservoir Cap&Over Cap CaCTI Reagent for T-TAS®01 Citrate Tube T-TAS®01 Total Thrombus Formation Analysis System Instrument
REF#19001 REF#19003 REF#19004   REF#18001

 

PERFORMANCE

Dabigatran (factor IIa inhibitor) or Rivaroxaban (factor Xa inhibitor) was spiked to healthy blood in the presense or absence of aspirin and AR-C66096 (P2Y12 antagonist). AUC and OT varied in dose-dependent manner. 

[Source]:

K Hosokawa, et. Al: PLoS One 9(1):e86491 (2014),Comparative Evaluation of Direct Thrombin and Factor Xa Inhibitors with Antiplatelet Agents under Flow and Static Conditions: An In Vitro Flow Chamber Model. 

PRODUCT INFORMATION

 

Required but not provided in AR chip package

T-TAS® 01 Total Thrombus Formation Analysis System Instrument

AR Chip & HD Chip Reservoir set for T-TAS® 01

CaCTI Reagent for T-TAS® 01

Citrate tubes (BD Life Sciences BD Vacutainer® REF#368273)

 

Physical specifications of T-TAS® 01 Instrument

Dimensions

(L x W x H) 36 x 32 x 24.7 cm

Weight

6.0 kg

Operating Conditions

Temperature: 20-30 °C

Relative Humidity: 20-80%

ORDERING INFORMATION

ITEM

  REF

T-TAS ®01 Total Thrombus Formation Analysis System Instrument

  18001

AR Chip for T-TAS® 01 (20 Chips)

  19001

AR Chip & HD Chip Reservoir set for T-TAS®01(100 sets)

  19003

CaCTI Reagent for T-TAS®01 (20 assays)

  19004

REFERENCES

  1. K Hosokawa, et. Al.: J Thromb Haemost 9(10), p2029-2037(2011), A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions.
  2. K Hosokawa, et. al: PLoS One 9(1):e86491 (2014), Comparative Evaluation of Direct Thrombin and Factor Xa Inhibitors with Antiplatelet Agents under Flow and Static Conditions: An In Vitro Flow Chamber Model
  3. S Ichikawa, et. al.: Circ J 83(6), p1309-1316(2019), Impact of Total Antithrombotic Effect on Bleeding Complications in Patients Receiving Multiple Antithrombotic Agents.
  4. M Ishii, et. al.: Int J Cardiol Heart Vasc 23:100346(2019), Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation – The ATTRACTIVE-TTAS study.
  5. K Hosokawa, et. al: PLoS One 9(1):e86491 (2014), Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
  6. M Ito, at. al.: J Am Heart Assoc 5(1):e002744 (2016), Total Thrombus-Formation Analysis System (T-TAS) Can Predict Periprocedural Bleeding Events in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
  7. O Borst, et. al.: Blood Adv 2(6), p715-730(2018), Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.
  8. K Yamamoto, et. al.: Thrombosis J 17, 17 (2019), Effects of glycemic control and hypoglycemia on Thrombus formation assessed using automated microchip flow chamber system: an exploratory observational study.
  9. K Derszniak, et al.: Front Pharmacol 10:68 (2019), Comparison of Effects of Anti-thrombin Aptamers HD1 and HD22 on Aggregation of Human Platelets, Thrombin Generation, Fibrin Formation, and Thrombus Formation Under Flow Conditions.
  10. K Kikuchi, et. al.: Sci Reports 8:15844 (2018), Uric acid enhances alteplase-mediated thrombolysis as an antioxidant.
  11. S Yamada, et. al.: Exp. Anim. 68(2), p137-146,(2019), Comparison between blood coagulability in the intra-atrial and peripheral regions during the acute phase after rapid atrial pacing.
  12. C Klatt, et. al.: J Clin Invest 128(9),p3906-3925(2018), Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis. 

Note: Most of above studies were performed by T-TAS PLUS.

IMPORTANT NOTES

The T-TAS 01 AR chip is FOR RESEARCH USE ONLY (RUO).

Not for medical, diagnostic nor other use.

PL Chip for T-TAS01 is available for in vitro diagnostic use only in the the United States and EU Copyright © 2020 FUJIMORI KOGYO CO.,LTD. All Rights Reserved.